Key result
DAPT de-escalation reduces major bleeding ~57% versus standard DAPT without increasing MACE.
Why the study?
The relative efficacy and safety of de-escalation, abbreviation, and standard potent P2Y12 inhibitor–based DAPT strategies after ACS remain uncertain.
Does DAPT de-escalation or abbreviated DAPT reduce major adverse cardiovascular events or bleeding in patients after acute coronary syndrome compared to standard 12-month DAPT?
Meta-Analysis (n=20,673)
Does DAPT de-escalation or abbreviated DAPT reduce major adverse cardiovascular events or bleeding in patients after acute coronary syndrome compared to standard 12-month DAPT?
Following acute coronary syndrome, both DAPT de-escalation and abbreviated DAPT followed by P2Y12 monotherapy effectively reduce bleeding risk and net adverse clinical events without compromising ischemic protection compared to standard 12-month DAPT.
Supports modified DAPT strategies to reduce bleeding in ACS; extends RCT evidence favoring de-escalation or abbreviation over standard 12-month therapy.
Background Potent P2Y12 inhibitor–based dual antiplatelet therapy (DAPT) is the default antiplatelet strategy after acute coronary syndrome (ACS), though de-escalation to clopidogrel-based DAPT and abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy are increasingly adopted to mitigate bleeding risk. However, their relative efficacy and safety remain uncertain. Methods Network meta-analyses of randomized controlled trials were performed to compare three guideline-endorsed strategies: (1) short-term potent P2Y12 inhibitor–based DAPT de-escalation to clopidogrel-based DAPT, (2) Abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy, and (3) standard 12-month potent P2Y12 inhibitor–based DAPT. Primary efficacy endpoint was major adverse cardiovascular events (MACE). Secondary efficacy endpoints included all-cause mortality, cardiovascular mortality, myocardial infarction, stent thrombosis, and stroke. Primary safety endpoint was major bleeding. The key net clinical endpoint was net adverse clinical events (NACE). PROSPERO (CRD420251144892) Results Seven randomized controlled trials involving 20,673 patients were included. Both the de-escalation and abbreviation strategies significantly reduced major bleeding (RR 0.43, 95% CI 0.25-0.74, p=0.002; and RR 0.43, 95% CI 0.33-0.58, p<0.001, respectively) and NACE (RR 0.54, 95% CI 0.41-0.70, p<0.001; and RR 0.72, 95% CI 0.61-0.84, p<0.001, respectively) without increasing MACE or other ischemic outcomes. Indirect comparison indicated that de-escalation vs abbreviation strategies demonstrated comparable MACE, NACE and bleeding outcomes. Conclusions Following ACS, both de-escalation to clopidogrel-based DAPT and abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy effectively reduce bleeding risk without compromising ischemic protection. Given that the only available comparison between the two simplified strategies was indirect and showed comparable MACE and NACE outcomes, further research is warranted to determine the optimal individualized approach.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) conducted a meta-analysis in Acute Coronary Syndrome (n=20,673). De-escalation to clopidogrel-based DAPT or abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy vs. Standard 12-month potent P2Y12 inhibitor-based DAPT was evaluated on Major bleeding (Primary safety endpoint; de-escalation vs standard DAPT) (RR 0.43, 95% CI 0.25-0.74, p=0.002). Both DAPT de-escalation and abbreviation strategies significantly reduced major bleeding compared to standard DAPT (RR 0.43; 95% CI 0.25-0.74; p=0.002 for de-escalation) without increasing MACE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: